Screener
Axsome Therapeutics AXSM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's cash & equivalents?
- Axsome Therapeutics (AXSM) reported cash & equivalents of $305.11M in Q1 2026.
- How has Axsome Therapeutics's cash & equivalents changed year-over-year?
- Axsome Therapeutics's cash & equivalents increased by 1.4% year-over-year, from $300.91M to $305.11M.
- What is the long-term trend for Axsome Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Axsome Therapeutics's cash & equivalents has grown at a 11.9% compound annual growth rate (CAGR), from $183.88M to $322.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Axsome Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude